Physician profile
Neel Mann
NPI 1881652923
$1,572.34
in general payments reported to CMS, 2019-2025
12 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.25 · 2020: $79.31 · 2021: $91.57 · 2022: $68.13 · 2023: $309 · 2024: $500 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,234.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $569.54 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $410.23 | 2020-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $116.71 | 2025 | Zerbaxa |
| Covidien Lp | $99.25 | 2019 | |
| Melinta Therapeutics, LLC | $84.63 | 2022-2023 | Vabomere, Kimyrsa, Orbactiv |
| Pfizer INC. | $76.86 | 2023-2024 | |
| Mallinckrodt Hospital Products INC. | $73.03 | 2024-2025 | Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.14 | 2024-2025 | Jardiance |
| Vifor Pharma, INC. | $29.51 | 2023 | Korsuva, Veltassa |
| Janssen Biotech, INC. | $25.00 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $21.98 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.46 | 2025 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neel Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.